Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9914008 | 1.00 | FUCA1 (0.54) | FUCA1GLASMN1; SMN2CA9CA2 | |
| SCHEMBL9914035 | 1.00 | FUCA1 (0.54) | FUCA1GLASMN1; SMN2CA9CA2 | |
| SCHEMBL12899990 | 0.98 | FUCA1 (0.51) | FUCA1GLASMN1; SMN2CA9CA2 | |
| SCHEMBL15978525 | 0.84 | FUCA1 (0.40) | FUCA1GLACA9CA2CA1 | |
| SCHEMBL13951673 | 0.83 | GLA (0.41) | FUCA1GLA | |
| SCHEMBL30483914 | 0.81 | PYGB (0.47) | GLA | |
| SCHEMBL9235423 | 0.81 | PYGB (0.47) | GLA | |
| SCHEMBL9915177 | 0.80 | FUCA1 (0.41) | FUCA1GLACA9CA2CA1 | |
| SCHEMBL17124769 | 0.80 | FUCA1 (0.39) | FUCA1CA9CA2CA12CA1 | |
| SCHEMBL20786630 | 0.79 | GLA (0.49) | GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | FUCA1 305/4885GLA 265/4885SMN1; SMN2 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.